ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has received an average recommendation of “Hold” from the six research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $5.50.
Several brokerages have recently issued reports on ZIOP. BidaskClub upgraded shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating in a research report on Thursday. Zacks Investment Research cut shares of ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a research report on Thursday, December 20th. Finally, Raymond James upgraded shares of ZIOPHARM Oncology from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a research report on Thursday, November 15th.
Shares of NASDAQ ZIOP traded up $0.10 during mid-day trading on Friday, hitting $3.61. 3,779,640 shares of the company’s stock traded hands, compared to its average volume of 1,618,873. The stock has a market capitalization of $563.96 million, a price-to-earnings ratio of -7.52 and a beta of 2.59. ZIOPHARM Oncology has a 1 year low of $1.56 and a 1 year high of $5.00.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.
Further Reading: How can you know how many shares are floating?
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.